Chart Review of Patients Undergoing Ketamine Treatments for Depression

This retrospective study reviews clinical charts from April 1, 2022 to June 29, 2025 to describe patient characteristics, treatment parameters, safety, and clinical outcomes following induction-phase intravenous racemic ketamine for treatment-resistant depression in a real-world outpatient centre.

Data include demographics, treatment course during the induction phase, adverse events, and prior neuromodulation history; sampling is non-probability and reflects routine clinical practice at the Ontario Ketamine and Infusion Centre.